Drug Profile
ISIS 14803
Latest Information Update: 03 Mar 2005
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C